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Abstract: Drug efficacy might differ from clinical trial results when performed in clinical 
daily conditions. Therefore, it is mandatory to conduct trials about effectiveness to improve 
external validity. This post-authorization, open-label, noncontrolled, prospective, multicenter, 
observational, and naturalistic trial was designed to search for factors influencing the racecadotril 
overall effect on childhood acute watery diarrhea in a real-world setting of Venezuela. There were 
3,873 children with acute watery diarrhea treated with racecadotril, an enkephalin breakdown 
blocker plus oral rehydration therapy by 97 pediatricians. Evaluations were carried out daily 
until emission of two consecutive formed stools or absence of watery bowel movements for 
24 hours. The primary end-point was time-to-relief, defined as the time from first racecadotril 
dose to the last watery bowel movement time. Age, gender, nursing type, nursing status dur-
ing diarrhea, diarrhea severity, and co-medication were considered as factors in the statistical 
analysis. The primary end-point was evaluated by factors using UNIANOVA, and post-hoc 
tests were done. A multiple regression analysis was carried out to identify factors affecting 
drug performance, racecadotril effectiveness and tolerability overall assessment was searched 
by physicians and patients, and inter-observer agreement was evaluated by kappa statistics. 
The mean time-to-relief was 18.5 ± 12.5 hours [95% confidence interval 17.9–19.0] and the 
diarrhea severity was the only variable with significant and independent weight on racecadotril 
effectiveness explaining 23% of time-to-relief variance, but even in severe diarrhea cases this 
time was less than 24 hours. High agreement about satisfactory perception on effectiveness and 
tolerability was reached among physicians and patients. In conclusion, the racecadotril overall 
effect, evaluated in a real-world setting of Venezuela, was in agreement with results of some 
earlier controlled trials. It was only influenced by severity of diarrhea episode, as well as being 
considered an effective and well tolerated treatment by physicians and patients.
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Introduction
Results of drug efficacy trials are affected by less controlled conditions of clinical daily 
practice.1 Therefore, the performance of a drug might be slightly different from that of 
more controlled settings, such as an experimental clinical assessment. This is why it is 
so important to show the performance of a drug in a real-world setting, once its efficacy 
has already been shown, in order to extend external validity of these results.   Nutritional, 
socioeconomic and cultural factors, as well as co-prescription and   co-morbidity 
might have some influence on drug effect of controlled trials,   especially in diarrhea, 
a pathology influenced by multiple variables related to poverty and impaired sanitary Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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conditions, as seen in a Venezuelan ordinary clinical setting. 
Therefore, it is necessary to show effectiveness, ie, evaluate 
drug performance beyond controlled clinical trials.1–4
Provided that it is necessary to know overall performance 
of a drug to estimate its therapeutic utility, efficacy data from 
controlled trials are not enough. It is also relevant to evaluate 
effectiveness data obtained from routine clinical practice 
because both are complementary.5 Effectiveness studies 
improve external validity of experimental trials because 
they are performed on larger noncontrolled samples from 
real-world patients.6–7
Acute childhood diarrhea is a disease influenced by 
socioeconomic issues which have an impact on evolution 
and outcomes; in Venezuela, diarrhea is a main cause of 
mortality in children younger than five years, only exceeded 
by respiratory diseases. In addition, acute diarrhea has high 
morbidity figures and also demands a great consumption of 
economic resources.8
Racecadotril, a pro-drug metabolized to thiorphan, its 
active metabolite, is an enkephalin breakdown blocking 
agent which inhibits intestinal hypersecretion in acute watery 
diarrhea and whose efficacy and safety has been proven in 
European and Latin-American countries in controlled clini-
cal trials.9–13 To our knowledge racecadotril performance in a 
real world setting, having taken into account factors affecting 
its effectiveness, has not been studied so far. The objective 
of this study, using a naturalistic approach14 and data from 
Racecadotril Post-authorization Record (RPR), was to pro-
vide quantitative data about racecadotril overall effect in acute 
watery diarrhea and identify potential modifying factors in 
children coming from a real-world setting.
Patients and methods
The RPR was an initiative carried out simultaneously in 
13 regions of Venezuela from September 2005 (first patient 
recorded) until April 2006 (last patient recorded). It was 
aimed at providing a systematic record about clinical and 
therapeutic topics relating to the use of racecadotril by 
pediatricians in children with acute watery diarrhea in a 
noncontrolled setting, and also to get a database to search top-
ics concerning to racecadotril performance in a Venezuelan 
ordinary clinical practice. This open-label, noncontrolled, 
prospective, multicenter, observational, and naturalistic study 
is the first collaboration of RPR Group. Sample collection 
was completed in two timeframes, the first one lasting from 
September until December 2005 in which 666 children were 
recruited and evaluated by 27 physicians and the second one 
from January to April 2006 in which 3,107 more patients 
were included by 70 pediatricians. The final sample was 
3,873 children, of which 3,679 (94.9%) were analyzed after 
excluding those with incomplete data.
Case report form (CRF)
A group of three pediatricians (MD, LM, and MG†), highly 
trained in acute diarrhea management, assessed the feasibil-
ity of recording number, time, and characteristics of bowel 
movements (BMs) during diarrhea in outpatients by parents 
at home after careful training by physicians. A first draft 
of CRF was designed which included a set of clinical and 
demographic data and was evaluated by them for feasibility 
and comprehensiveness using a simple questionnaire ad hoc. 
Disagreements were solved by consensus and a final CRF 
was completed, after agreement was achieved by evaluators 
and suggested changes were made.
Data collection
Ninety seven pediatricians, selected according to predefined 
criteria, formed the RPR Group and recruited patients in a 
consecutive fashion; they were supported by a 40-member 
team which carried out the logistical operations all over 
the country, such as delivery of study items to physicians. 
Completed CRFs were sent back via mail to the headquar-
ters based in Guarenas city and data were introduced into a 
database after excluding CRFs with serious missing data, 
namely those relating to duration of diarrhea.
study medication
The study medication consisted of granulated powder in 
sachets containing 10 and 30 mg of racecadotril (Hidrasec®, 
Ferrer Grupo, Barcelona, Spain), a pro-drug metabolized to 
thiorphan, an enkephalin breakdown blocker and intestinal 
water hypersecretion inhibitor agent in acute watery diarrhea, 
indicated for children older than three months old at doses 
of 1.5 mg/kg/dose ter in die.
Patients
A total of 3,873 patients aged three months to 12 years old 
and suffering from acute watery nonspecific   diarrhea from 
13 regions of Venezuela (Caracas DC, Zulia, Mérida, 
Táchira, Lara, Aragua, Carabobo, Vargas, Miranda,   Monagas, 
  Anzoátegui, Nueva Esparta, and Bolívar), were treated 
by 97 pediatricians in an outpatient setting. Diarrhea was 
defined as three or more watery stools 24 hours prior to first 
racecadotril dose. Because of missing data among variables 
and restriction of analysis to paired data, assessments of indi-
vidual parameters might have a different number of patients. Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Because this was a noninterventional surveillance study, no 
restrictions were enforced regarding inclusion and exclu-
sion criteria of patients and the racecadotril was used by 
the physicians according to Venezuelan health authority’s 
regulations.
study parameters
Patients were included in the RPR according to the   judgment 
of pediatricians belonging to this research group. Evaluations 
were carried out by physicians at baseline and daily until 
stopping of watery BMs. Frequency of visits was adjusted 
according to disease severity and short admission periods 
were allowed if needed. Date and time of the first watery 
BM and total BMs in previous 24 hours were recorded. Age, 
gender, nursing type, diarrhea severity, nursing status during 
diarrhea, and co-medication were the clinical and demo-
graphic characteristics recorded. The first racecadotril dosing 
time was also recorded to get the time-to-relief (TTR), as 
have been used in other trials.15 During the trial, BMs were 
recorded daily for time and consistency by a self-assessment 
form filled in by the child’s parents at home. Finally, all 
  physicians in this trial were encouraged to inform any adverse 
drug effect (ADE) to Authorities Health, following usual 
procedures in Venezuela.
Biometric evaluation
The primary effectiveness endpoint of this analysis was 
TTR, considered a dependent variable in the statistical 
analysis and defined as the time between the first racecado-
tril dose given by physician and the start-point of the first 
24 hour period with no watery BMs. The watery stools were 
defined according to the Bristol Stool Scale.16 Patients were 
included in the database for final analysis if the racecadotril 
first   dosing time had been recorded in CRFs. Patients with 
missing data concerning to time or stool consistency during 
the follow-up were not analyzed because it was not possible 
to get the end-point.
TTR was statistically evaluated by UNIANOVA for 
patient characteristics: age, gender, nursing type (breastfeed-
ing, bottle feeding, or mixed feeding), nursing status during 
diarrhea (nursing or no nursing), co-medication, and diar-
rhea severity which were graded according to the number 
of watery stools in the 24 hour period prior to inclusion into 
the study (mild = 3–4, moderate = 5–7, and severe $ 8).15,17 
A post hoc test was used to identify potentially significant 
intra-group differences. Spearman’s rho test was used to 
examine significant correlations. A multiple regression 
analysis was used to estimate independent effects of   factors 
on the study end-point. Finally, diarrhea evolution was   plotted 
using Kaplan–Meier technique.18
A six-point Likert score, with Excellent as best score and 
Very poor as the worst one, was used to search physicians’ 
and patients’ (or parents’) evaluation of treatment effective-
ness for overall illness relief and for overall tolerability. The 
inter-observer agreement of both prior mentioned outcomes 
was done by quadratic-weighted kappa statistics.
The data were analyzed using the Statistical Package for 
Social Sciences (SPSS; 12.0 version SPSS Inc, Chicago, 
IL), and the Epidemiological Analysis from Tabulated Data 
(EPIDAT, 3.1 version Organización Panamericana de la 
Salud, Washington D.C.). A P value ,0.05 was considered 
significant.
Results
A total of 3,873 children aged three months to 12 years old 
with watery acute diarrhea of any etiology coming from 
13 regions of Venezuela were treated with racecadotril 
(1.5 mg/kg/dose ter in die) plus standard therapy including 
oral rehydration therapy (ORT) by 97 pediatricians of the 
RPR Group. After excluding 194 CRFs because of serious 
missing data, final sample for analysis was 3,679 patients, 
mainly younger than seven years old and consistent with 
acute diarrhea morbidity data in Venezuela.8 More than half 
(53.7%) were male and the sample age-weight ratio was over 
the 10th percentile, according to Venezuelan values (data not 
shown).19 At baseline, 24.3% of children were breast-fed, the 
rest had other types of lactation (bottle or mixed feeding). 
As usual in Venezuela, nursing was stopped during diarrhea 
in 33% of the children due to parents’ decision, not show-
ing any significant difference by age (χ2 = 3.06, P = 0.39). 
Approximately 83% of the patients had a moderate-to-severe 
diarrhea; however, this criterion was used only with com-
parative purposes and did not intend to reflect the current 
patient clinical state. The cases of severe diarrhea were 
mostly children younger than seven years old (93.4%) and 
80.73% of them were younger than four years. All patients 
were treated with ORT according to standard guidelines, 
and the most commonly used co-medication were probiotics 
(28.9%) (Table 1).
Racecadotril effect on TTR
The mean TTR was 18.5 ± 12.5 hours (95% confidence 
  interval [CI]: 17.9–19.0) and pre-treatment time, ie, the mean 
time from first watery stool to first racecadotril dose, was 
7.9 ± 7.8 hours (95% CI: 7.3–8.6), accordingly, the mean over-
all diarrhea time was 26.7 ± 23.6 hours (95% CI: 25.9–27.6), Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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taking into account our end-point criterion. The rate of 
recovery over time in the whole sample of children is show 
in Figure 1, using the Kaplan–Meier technique. The rate of 
unsolved diarrhea was defined as the persistence of watery 
stools at any time. The median duration of the primary end-
point overall was 18.48 hours (95% CI: 17.0–19.0), which 
means that 50% of the sample was free of watery stools 
18 hours after racecadotril first dose. Moreover, seven out of 
every 10 children had solved their watery diarrhea within the 
first 24 hours, 90% at 36 hours, and only 2% of the sample 
had watery diarrhea which lasted 56.6 ± 9.1 hours.
We performed a general linear model (UNIANOVA) to 
search potential associations among patient characteristics 
and TTR, considered a dependent variable in the model. 
A Bonferroni test was used to identify significant   intra-group 
differences. Diarrhea severity and co-  medication were the 
only variables showing statistical significant association 
with the end-point (Table 2). The longest watery stool time 
was seen in children with severe diarrhea and the post hoc 
analysis showed statistical significant differences among all 
diarrhea severity groups (P = 0.0001 for all comparisons).
To confirm this association, correlation between TTR and 
diarrhea severity was evaluated using Spearman’s rho test. 
We found a highly significant positive   correlation (r = 0.33, 
P = 0.0001), suggesting some influence of diarrhea severity 
on racecadotril effectiveness measured by TTR. Neverthe-
less, it should be noted that even in the severe diarrhea group, 
the mean of this time was less than 24 hours (Table 2).
All patients received ORT as standard treatment for 
  childhood diarrhea, following standard guidelines in 
  Venezuela, and racecadotril (1.5 mg/kg ter in die) was added 
as an adjuvant medication to reduce intestinal hypersecretion 
of watery diarrhea and to shorten the illness. There was a mar-
ginal difference among co-medication groups (Table 2). A sig-
nificant statistical difference was shown in post hoc test among 
children with antibiotic treatment with both racecadotril and 
probiotic groups (P = 0.017 and 0.042, respectively).
To examine the independent effect of clinical and   demographic 
factors on the overall result of racecadotril, measured as TTR, 
we performed a multiple regression model with the whole set of 
patients’ characteristics as independent variables. According to 
results of this model, diarrhea severity was the only variable with 
significant and independent weight, explaining 23% of variance 
corresponding to TTR in our patients (Table 3).
According to kappa values, there was high agreement 
among physicians and patients, or their parents, about 
the suitable perception of racecadotril effectiveness and 
tolerability; 0.66 (95% CI: 0.58–0.74), P = 0.00001 and 0.66 
(95% CI: 0.54–0.77), P = 0.00001, respectively. In addition, 
Excellent to Good categories for both effectiveness and 
tolerability reached 96.9% and 95.9% of overall agreement 
in each case (Figure 2). Neither admission was necessary nor 
were ADEs officially reported during this trial.
Discussion
Racecadotril efficacy has been proven in developed and devel-
oping countries as a treatment for acute childhood diarrhea 
in controlled clinical trials,9–13 which are considered the best 
standard to prove drug efficacy. However, performance in daily 
practice, ie, effectiveness, has not been researched so far.
To study racecadotril effect in a daily clinical practice 
  setting we used a naturalistic approach to show external 
Table 1 Clinical and demographic data of the study population
Pre-treatment time,* mean ± sD  
(95% Ci), hours
7.9 ± 7.8 (7.3-8.6)
Time-to-relief,** mean ± sD  
(95% Ci), hours
18.5 ± 12.5 (17.9-19.1)
Diarrhea overall time,*** mean ± sD  
(95% Ci), hours
26.7 ± 23.6 (25.9-27.6)
Age groups,20,21 %
  Younger infants (1-11 months of age)§ 28.2
  Older infants (12-23 months of age) 28.8
  Pre-school children (2-6 years of age) 35.0
  school children (7-12 years of age) 7.7
Weight, mean ± sD (95% Ci)
  global mean 13.3 ± 8.5 (13.0-13.7)
  Younger infants 7.9 ± 3.2 (7.7-8.1)
  Older infants 10.0 ± 2.3 (9.8-10.2)
  Pre-school children 16.5 ± 7.1 (16.0-16.9)
  school children 30.3 ± 11.8 (28.7-31.9)
gender, male %
  Male 53.7
nursing type %
  Breast feeding  24.3
  Bottle feeding  62.9
  Mixed feeding 12.8
nursing status %
  nursing  66.8
  no nursing 33.2
Diarrhea severity**** %
  Mild 17.5
  Moderate 41.0
  severe 41.5
Co-medication %
  ORT 100
  Probiotics 4.6
  Antibiotics 2.5
  Poypharmacy 37.3
Notes: *Time from first watery stool to first racecadotril dose; **Time from first 
racecadotril dose to last watery stool recorded; ***Time from first watery stool to 
last watery stool recorded; ****Total watery bowel movements 24 hours before 
treatment; §Only children older than three months of age were included according 
to product prescrition information.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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validity of phase III trials.14 This study was performed in a 
  real-word setting5 and included a large sample of children 
coming from different geographic areas of Venezuela. The 
end-point was TTR, as used in a number of controlled trials,9–12 
and was useful to describe diarrhea evolution in this trial.
Diarrhea definition is a problematic matter because is dif-
ficult to set normal stool consistency, especially in childhood. 
This is why there is a great variability in operational definition 
across clinical trials. Racecadotril controlled trials, using dif-
ferent operational diarrhea approaches, have shown recovery 
times ranging between 6.9 hours and 97.2 hours.10–13 On the 
other hand, a large community study carried out in Brazil 
showed a diarrhea mean time of 69.6 hours in 2,403 diarrhea 
episodes suffered by 1,156 children managed at home.22 We 
have shown a mean diarrhea duration of 18.5 hours, using TTR 
as recovery criterion, and considered it suitable to search the 
overall effect of an antihypersecretory agent like racecadotril in 
a real-world setting, such as this trial. The noncontrolled design 
was the main limitation of this study; hence, our results were 
confronted with those of controlled trials and epidemiological 
study carried out in Brazil. Therefore, we measured the varia-
tions in the health gains from using racecadotril in the real 
world. Racecadotril efficacy has been evaluated using a number 
of different outcomes including number of diarrheic stools, 
diarrhea duration, and stool output,9–12 which in turn could be 
considered the best end-point to assess the efficacy of a drug like 
racecadotril given their antisecretory profile in acute diarrhea. 
However, despite their more accurate value, its use implies a 
complex and unfeasible procedure for a trial like this which met 
3,873 children evaluated in an outpatient setting.
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Figure 1 Rates of recovery over time in children with acute watery diarrhea after racecadotril treatment. n = 3.679.
Table 2 Association among demographics and clinical character-
istics with time-to-relief.* n = 2.913
Mean ± SD P
Diarrhea severity
  Mild 12.9 ± 9.5  0.0001
  Moderate 15.6 ± 10.8
  severe 20.9 ± 13.3
Co-medication**
  none 17.4 ± 11.8 0.042
  Probiotics 18.0 ± 12.0
  Antibiotics 22.1 ± 19.9
  Polypharmacy 20.2 ± 13.5
Notes: *statistical analysis by UniAnOVA adjusted at age, nursing status, nursing 
type, co-medication, gender, and diarrhea severity; **Refers to any other drugs apart 
from troglitazone and racecadotril.
Table 3 Association among independent variables with time-to-
relief. n = 2.913
Independent variables β P VIF
Age -0.017 ns 1.02
gender -0.014 ns 1.00
nursing type 0.009 ns 1.02
Diarrhea severity 0.230 0.0001 1.01
nursing status -0.002 ns 1.00
Co-medication 0.032 ns 1.01
Note:  *Multiple  regression  analysis  with  time-to-relief  as  dependent  variable.
Abbreviations: VIF, variance-inflation factor (threshold # 4); NS, not significant.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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A greater effect on weight, height gain, and even in a child’s 
catch-up growth can be expected as the diarrhea   episodes 
become longer, showing the cumulative effects of diarrhea 
on intake, absorption, and use of nutrients.22 Racecadotril 
is considered a useful adjuvant in acute diarrhea to shorten its 
duration, as shown in this trial. Our results suggest that diarrhea 
severity and co-medication were the only variables associated 
with TTR, considered in this trial as an indicator of acute child-
hood diarrhea evolution after racecadotril treatment.
Diarrhea severity was the variable exerting the greatest 
weight on our recovery criterion, and the only one with 
significant effect in the regression model. Therefore, only 
diarrhea severity showed a potential impact on modifying 
the racecadotril effect on diarrhea evolution expressed by the 
study end-point. However, is noteworthy to mention that even 
in worst cases ($8 BMs/24 h) the TTR was no longer than 24 
hours (20.9 ± 13.3 h), around 70% less than those reported 
by Strina et al22 in their epidemiological study about natural 
history of acute diarrhea in Latin-American children coming 
from Brazil, taking into consideration possible inaccuracies 
about comparison related to diarrhea definitions.
Co-medication showed a weak association with the end-
point without any significant weight in the regression model. 
However, those children co-treated with antibiotics had the 
longest TTR, suggesting some negative effect of antibiotics 
on diarrhea evolution in our patients. Nevertheless, we cannot 
explain this finding because it exceeds the scope of this trial.
To our knowledge, this is the first racecadotril trial assessing 
in a simple measure, agreement among physicians and parents 
about global perception on the drug’s effectiveness and toler-
ability, considering potential differences on   expectation because 
of different points of view on illness. The kappa values23 showed 
a good perception about racecadotril performance as acute 
watery childhood diarrhea treatment in a real-world setting.
Data of this trial showed mean diarrhea duration of 
18.5 hours, using our recovery criterion, after racecadotril 
treatment as an adjuvant to ORT in a large group of children 
treated by their pediatricians in routine clinical practices of 
Venezuela and only influenced by severity of the acute diar-
rhea episode. This result is between the ranges published by 
controlled trials so far that have shown recovery times as short 
as seven hours and long as 97 hours, considering the controlled 
trials inconsistencies about the reporting outcomes. A recent 
systematic review24 carried out with the best randomized clini-
cal trials about racecadotril efficacy showing recovery times of 
6.9, 28, and 97 hours from active treatment groups of the main 
studies analyzed in this meta analysis.10,11,13 On the other hand, 
similar to results of the study by Cojocaru et al13 was published 
lately, another trial showing a diarrhea duration of four days in 
active treatment group. This is intriguing considering the results 
coming from the epidemiological study by Strina et al22 showing 
an overall diarrhea duration of three days without any pharma-
cological treatment and reflecting a picture of the natural history 
of childhood acute diarrhea in Latin-American countries. Our 
results showed shorter mean diarrhea duration than the above 
clinical trial (18.5 hours vs four days), however, our recovery 
time is closer to those from trials by Salazar-Lindo et al10 and 
Turck et al12 and cannot be explained by a mild and late   disease 
at baseline because at least 80% of our patients showed a moder-
ate to severe disease with a mean duration of eight hours before 
start of racecadotril treatment.
In conclusion, the racecadotril overall effect, evaluated in a 
real-world setting of Venezuela, was in agreement with results of 
some earlier controlled trials and was only influenced by severity 
of diarrhea episode, as well as being considered an effective and 
well tolerated treatment by physicians and patients.
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